Total Payments
$500,221
2024 Payments
$63,140
Companies
27
Transactions
215
Medicare Patients
161
Medicare Billing
$21,636
Payment Breakdown by Category
Consulting$381,036 (76.2%)
Other$64,264 (12.8%)
Travel$34,844 (7.0%)
Research$12,839 (2.6%)
Food & Beverage$7,237 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $381,036 | 41 | 76.2% |
| Travel and Lodging | $34,844 | 54 | 7.0% |
| Honoraria | $34,250 | 10 | 6.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,014 | 13 | 5.0% |
| Unspecified | $12,839 | 7 | 2.6% |
| Food and Beverage | $7,237 | 89 | 1.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,000 | 1 | 1.0% |
Payments by Type
General
$487,381
208 transactions
Research
$12,839
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $170,783 | 23 | $0 (2023) |
| iSchemaView, Inc. | $120,000 | 3 | $0 (2024) |
| Horizon Pharma plc | $31,446 | 18 | $0 (2018) |
| Medtronic USA, Inc. | $26,042 | 22 | $0 (2018) |
| Medtronic Vascular, Inc. | $22,207 | 42 | $0 (2018) |
| F. Hoffmann-La Roche AG | $21,756 | 12 | $0 (2024) |
| AstraZeneca UK Limited | $15,216 | 9 | $0 (2019) |
| Biogen, Inc. | $14,441 | 7 | $0 (2023) |
| Janssen Research & Development, LLC | $13,484 | 18 | $0 (2020) |
| PORTOLA PHARMACEUTICALS, INC. | $9,657 | 13 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,140 | 8 | iSchemaView, Inc. ($40,000) |
| 2023 | $71,047 | 9 | iSchemaView, Inc. ($40,000) |
| 2022 | $40,950 | 2 | iSchemaView, Inc. ($40,000) |
| 2021 | $29,253 | 9 | Genentech, Inc. ($13,440) |
| 2020 | $46,797 | 7 | Genentech, Inc. ($42,695) |
| 2019 | $121,281 | 41 | Genentech, Inc. ($83,600) |
| 2018 | $52,518 | 67 | Medtronic Vascular, Inc. ($13,493) |
| 2017 | $75,233 | 72 | Horizon Pharma plc ($28,335) |
All Payment Transactions
215 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/06/2024 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 05/13/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $10,347.50 | General |
| 05/13/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $6,633.70 | General |
| 05/13/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $392.66 | General |
| 05/13/2024 | F. Hoffmann-La Roche AG | — | Travel and Lodging | Cash or cash equivalent | $356.87 | General |
| 05/13/2024 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $106.48 | General |
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,102.96 | Research |
| Study: Tenecteplase in stroke patients between 4 5 and 24 hours | ||||||
| 01/31/2024 | iSchemaView, Inc. | — | Consulting Fee | Cash or cash equivalent | $40,000.00 | General |
| 10/25/2023 | NESTLE HEALTHCARE NUTRITION INC. | VOWST (Biological) | Food and Beverage | Cash or cash equivalent | $124.98 | General |
| Category: GI | ||||||
| 09/21/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,800.00 | General |
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $686.96 | Research |
| Study: Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischaemic Stroke and Evidence of Salvageable Tissue: Results From the Phase III TIMELESS Trial | ||||||
| 06/30/2023 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.30 | Research |
| Study: EFFICACY AND SAFETY OF TENECTEPLASE IN PATIENTS WITH LATE-WINDOW ACUTE ISCHEMIC STROKE AND EVIDENCE OF SALVAGEABLE TISSUE: RESULTS FROM THE PHASE 3 TIMELESS TRIAL | ||||||
| 04/14/2023 | ARGENX US, INC. | — | Consulting Fee | Cash or cash equivalent | $5,175.00 | General |
| 04/06/2023 | Biogen, Inc. | — | — | Cash or cash equivalent | $1,187.00 | Research |
| Study: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | ||||||
| 02/15/2023 | Apollo Endosurgery US Inc | OverStitch Endoscopic Suturing System (Device) | Food and Beverage | In-kind items and services | $111.08 | General |
| Category: ENDOSCOPIC TISSUE APPROXIMATION DEVICE | ||||||
| 02/08/2023 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $15,600.00 | General |
| 01/14/2023 | iSchemaView, Inc. | — | Consulting Fee | Cash or cash equivalent | $40,000.00 | General |
| 11/17/2022 | Biogen, Inc. | — | — | Cash or cash equivalent | $950.00 | Research |
| Study: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | ||||||
| 01/15/2022 | iSchemaView, Inc. | — | Consulting Fee | Cash or cash equivalent | $40,000.00 | General |
| 12/09/2021 | Genentech, Inc. | Activase (Biological), Cathflo Activase, TNKase | Consulting Fee | Cash or cash equivalent | $12,000.00 | General |
| Category: Metabolism & Primary Care | ||||||
| 11/17/2021 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 09/23/2021 | Genentech, Inc. | TNKase (Biological) | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| Category: Metabolism & Primary Care | ||||||
| 07/26/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,790.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/16/2021 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,163.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/11/2021 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Consulting Fee | Cash or cash equivalent | $2,060.00 | General |
| Category: Iron Deficiency Anemia | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | Biogen, Inc. | $8,550 | 2 |
| Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction | Biogen, Inc. | $2,137 | 2 |
| Tenecteplase in stroke patients between 4 5 and 24 hours | F. Hoffmann-La Roche AG | $1,103 | 1 |
| Efficacy and Safety of Tenecteplase in Patients With Late-Window Acute Ischaemic Stroke and Evidence of Salvageable Tissue: Results From the Phase III TIMELESS Trial | F. Hoffmann-La Roche AG | $686.96 | 1 |
| EFFICACY AND SAFETY OF TENECTEPLASE IN PATIENTS WITH LATE-WINDOW ACUTE ISCHEMIC STROKE AND EVIDENCE OF SALVAGEABLE TISSUE: RESULTS FROM THE PHASE 3 TIMELESS TRIAL | F. Hoffmann-La Roche AG | $362.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 49 | 74 | $31,750 | $7,852 |
| 2021 | 3 | 44 | 64 | $22,876 | $5,940 |
| 2020 | 4 | 68 | 89 | $30,134 | $7,845 |
Total Patients
161
Total Services
227
Medicare Billing
$21,636
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 35 | $9,450 | $2,554 | 27.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $11,355 | $2,281 | 20.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 13 | $6,812 | $1,554 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 11 | 11 | $4,133 | $1,463 | 35.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 35 | $12,880 | $3,082 | 23.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 16 | 17 | $5,652 | $2,159 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 12 | 12 | $4,344 | $698.80 | 16.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 41 | $15,088 | $4,000 | 26.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 13 | 13 | $6,668 | $1,526 | 22.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 21 | $5,124 | $1,421 | 27.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 14 | 14 | $3,254 | $896.79 | 27.6% |
About Dr. Gregory Albers, MD
Dr. Gregory Albers, MD is a Neurology healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205889698.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Albers, MD has received a total of $500,221 in payments from pharmaceutical and medical device companies, with $63,140 received in 2024. These payments were reported across 215 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($381,036).
As a Medicare-enrolled provider, Albers has provided services to 161 Medicare beneficiaries, totaling 227 services with total Medicare billing of $21,636. Data is available for 3 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Vascular Neurology
- Location Stanford, CA
- Active Since 05/18/2006
- Last Updated 11/09/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1205889698
Products in Payments
- Activase (Biological) $140,101
- PRIMARY CARE - DISEASE STATE (Drug) $31,446
- Solitaire (Device) $22,077
- XARELTO (Drug) $9,484
- Cathflo Activase (Biological) $7,648
- ANDEXXA (Biological) $7,508
- XIFAXAN (Drug) $5,617
- DS1040 (Drug) $4,208
- BRILINTA (Drug) $3,953
- Avigo (Device) $2,720
- INJECTAFER (Drug) $2,320
- ANDEXXA (Drug) $2,149
- JARDIANCE (Drug) $1,549
- TNKase (Biological) $1,440
- MindFrame Capture LP (Device) $1,200
- Reveal LINQ (Device) $504.62
- ZENPEP (Drug) $130.20
- VOWST (Biological) $124.98
- OverStitch Endoscopic Suturing System (Device) $111.08
- TREVO (Device) $100.90
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Stanford
John Day, Md, MD
Neurology — Payments: $367,934
Neurology $367,934
Robert Cowan, Md, MD
Neurology — Payments: $253,351
Neurology $253,351
Josef Parvizi, Md, Phd, MD, PHD
Neurology — Payments: $215,697
Neurology $215,697
Chitra Venkatasubramanian, Md, MD
Neurology — Payments: $206,735
Neurology $206,735
Babak Razavi, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $121,290
Neurology $121,290
Kimford Meador, Md, MD
Neurology — Payments: $72,646
Neurology $72,646